Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ala7.0
Alpha Lipoic Acid – Forschung
Hilft wahrscheinlich
93 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Alpha Lipoic Acid scheint in 17 von 20 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1999–2026 mit einer typischen Studiengröße von 137 Teilnehmenden.
Basierend auf 93 Studien · 32 Meta-Analysen · 21 RCTs · 894,389 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
17geholfen2unklar1nicht geholfen· 73 weitere ohne bewertete Effektdaten
Nach Outcome
Glucose & metabolicVerbesserte Glukoseverwertung und Insulinsensitivität · 2-4 Wochen · Verbessert die Insulinsensitivität und unterstützt die mitochondriale Energie · 4-12 Wochen
Heart & blood pressureVerbessert die Endothelfunktion und reduziert oxidativen Stress · 8-12 Wochen
Überwiegend Mechanismus / Beobachtung6 Studien
InflammationVerbesserte Insulinsensitivität und Blutzuckerkontrolle · 4-12 Wochen
Hilft wahrscheinlich6 Studien
Cholesterol & lipidsVerbessert die Endothelfunktion und reduziert oxidativen Stress · 8-12 Wochen
Überwiegend Mechanismus / Beobachtung5 Studien
Liver healthAntioxidativer Kofaktor für die Leberfunktion · 4-8 Wochen
Überwiegend Mechanismus / Beobachtung3 Studien
Cognitive function
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 71 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
79%
über Studien hinweg
Untersuchte Personen
894k
typische Studie: 137 Personen
Stärkste Designs
53
32 gepoolt, 21 randomisiert
Zeigte Nutzen
85%
17/20 Studien
Wie lange Studien liefen
1–3 Monate
3
3+ Monate
4
Untersuchte Populationen
Patients with burning mouth syndrome5
General population4
Patients with diabetic polyneuropathy3
Adults3
Aktives Forschungsgebiet
79 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
199920122026
1Intermediate disease markersMeta-Analysen=704 · large study2025
Prospero registration number CRD42023450239.
Luo Y, Zhang J, Guo H. · BMJ open (2025)
Begg's test indicated no evidence of publication bias.
Conclusions No significant associations were detected between ALA intake and intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR and FBS levels, in overweight or obese adults.
Further research is needed to explore the potential associations of ALA, especially in high-risk populations with metabolic disorders, by employing longer intervention durations, higher dosages and optimised formulations.
3Hemoglobin levelsMeta-AnalyseCited 4×n=529 · large study2024
ALA supplementation had no statistically significant effect on iron-related parameters.
Sharifi-Zahabi E et al. · International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
In subgroup analysis, ALA significantly increased hemoglobin in patients with hematological disorders (WMD = 1.23 g/dL; 95% CI: 1.00, 1.45 g/dL; I2 = 96.6%, p < 0.001) and in studies with durations longer than 8 weeks (WMD = 1.03 g/dL; 95% CI: 0.82, 1.25 g/dL; I2 = 96.5%, p = 0.02).
ALA supplementation had no statistically significant effect on iron-related parameters.
4C-reactive protein levelsMeta-AnalyseCited 5×n=947 · large study2023
In summary, ALA supplementation improves inflammatory markers without any evidence of non-linear association to dose or duration of the trial.
Vajdi M et al. · International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2023)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
The weighted mean differences (WMD) and 95% confidence intervals (CI) were calculated to evaluate the pooled effect size.
The findings of the meta-analysis showed that ALA supplementation significantly reduced CRP (WMD: -0.69 mg/L, 95% CI: -1.13, -0.26, P=0.002), IL-6 (WMD: -1.83 pg/ml, 95% CI: -2.90, -0.76, P=0.001), and TNF-α concentrations (WMD: -0.45 pg/ml, 95% CI: -0.85, -0.04, P=0.032).
No evidence of departure from linearity was observed between dose and duration of the ALA supplementation on serum CRP, IL-6 and TNF-α concentration.
5Endothelial functionSystematische ÜbersichtCited 11×n=1,106 · large study2022
In conclusion, these results suggest improvement of endothelial function, but not endothelium-independent vasodilation as a potential mechanism by which ALA attenuates cardiovascular diseases.
Hajizadeh-Sharafabad F et al. · Critical reviews in food science and nutrition (2022)
Of 11 trials that evaluated endothelial function by methods such as flow-mediated dilation (n = 7), reactive hyperemia (n = 2) and ACh-induced endothelium-dependent vasodilation (n = 2), 10 reported a significant improvement in endothelial function.
In contrast, none of six trials examining the response of endothelium-independent vasodilation reported the favorable impact.
The effect of ALA on arterial stiffness measures has been poorly studied.
These findings suggest that ALA is a viable supplement to improve some of the glycemic and inflammatory biomarkers.
Rahimlou M et al. · Clinical Nutrition ESPEN (2019)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
The results demonstrated the significant effect of ALA on Fasting Blood Sugar (FBS) (weighted mean difference (WMD)) = -6.57, 95% confidence interval (CI: -11.91 to -1.23, P = 0.016), Hemoglobin A1c (HbA1c) (WMD = -0.35, 95% CI: -0.55 to -0.15, P = 0.004).
Significant effects were also seen on Tumor Necrosis Factor Alpha (TNF-α) (WMD = -1.57, 95% CI: -2.29 to -0.85, P < 0.05), Interleukin 6 levels (IL-6) (WMD = -1.15, 95% CI: -1.58 to -0.72, P < 0.001), and C-reactive protein (CRP) (WMD = -0.31, 95% CI: -0.47 to -0.16).
No effect was detected for ALA on insulin and the homeostatic model assessment of insulin resistance (HOMA-IR).
The use of certain dietary supplements has resulted in a significant decrease in migraine prophylaxis.
Talandashti MK et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025)
In adults, compared with placebo, these supplements did not significantly affect other outcomes, and omega-3 supplementation did not yield a statistically significant reduction in any of these outcomes.
The use of certain dietary supplements has resulted in a significant decrease in migraine prophylaxis.
Further clinical trials of high quality appear to be beneficial.
These findings revealed that ALA supplementation slightly but significantly reduced blood levels of high-sensitivity C-reactive protein, total cholestrol, and low-density lipoprotein cholesterol, but did not affect IL-6, malondialdehyde, high-density lipoprotein cholesterol, weight, body mass index, iron, and hemoglobin in patients with CKD.
Rezaei H et al. · Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation (2025)
Spürbar Nutzen
← SchlechterKein EffektBesser →
However, compared to the control group, total cholestrol levels were considerably lower in CKD patients (WMD = -5.48 mg/dL, 95% CI: -10.55, -0.41, I2 = 0.0%, P = .50).
Moreover, the sensitivity analyses showed that pooled WMDs for low-density lipoprotein cholesterol levels were significantly changed (-6.88 mg/dL, 95% CI, -12.78, -0.98).
While topical clonazepam, alpha-lipoic acid, and low-level laser therapy (LLLT) emerged as potentially effective options in several RCTs, the overall strength of evidence is limited.
Rossetti A et al. · Clinical oral investigations (2025)
While topical clonazepam, alpha-lipoic acid, and low-level laser therapy (LLLT) emerged as potentially effective options in several RCTs, the overall strength of evidence is limited.
These therapies appear promising, but further high-quality, larger randomized trials are needed before firm first-line recommendations can be made.
12Systematische ÜbersichtCited 14×n=22 · very small study2024
Based on the review, we cannot recommend any supplement use for the management of CIPN, although further research into N-acetyl-cysteine, l-carnosine, crocin, and magnesium is warranted.
Frediani JK et al. · Pain practice : the official journal of World Institute of Pain (2024)
Based on the review, we cannot recommend any supplement use for the management of CIPN, although further research into N-acetyl-cysteine, l-carnosine, crocin, and magnesium is warranted.
Acetyl-l-carnitine was found to be likely ineffective or harmful.
14Therapeutic outcomes in diabetic peripheral neuropathyMeta-AnalyseCited 7×2024
For diabetic peripheral neuropathy, the triple-combination therapy may be more effective than monotherapy or dual therapy.
Ran GL et al. · Journal of diabetes and its complications (2024)
Sehr groß Schaden
← SchlechterKein EffektBesser →
Likely real
Therapeutic outcomes were better in the experimental group than in the control group (odds ratio: 3.74; 95 % confidence interval: 2.57-5.45; I2 = 0 %; p < 0.00001).
Compared with the control group, the experimental group exhibited significant improvements in median motor nerve conduction velocity (MNCV), sensory nerve conduction velocity (SNCV), peroneal MNCV, peroneal SNCV, and vibration perception thresholds (VPT) in the left and right lower limbs.
For diabetic peripheral neuropathy, the triple-combination therapy may be more effective than monotherapy or dual therapy.
16Pain reduction in burning mouth syndromeMeta-AnalyseCited 19×2023
More randomized controlled trials comparing treatments against placebo are encouraged to confirm the evidence and test possible alternative treatments (PROSPERO CRD42021255039).
Alvarenga-Brant R et al. · Journal of dental research (2023)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Mean difference (MD) and 95% CI were calculated for continuous outcomes.
The anxiolytic (clonazepam) probably reduces the pain of BMS when compared with placebo (MD, -1.88; 95% CI, -2.61 to -1.16; moderate certainty).
Photobiomodulation therapy (MD, -1.90; 95% CI, -3.58 to -0.21) and pregabalin (MD, -2.40; 95% CI, -3.49 to -1.32) achieved the minimal important difference of a beneficial effect with low or very low certainty.
17Pain reduction in diabetic neuropathyMeta-AnalyseCited 11×2023
In comparison to the use of a placebo, the findings suggest that ALA does not exhibit significant differences in terms of pain reduction and different functional scales.
Orellana-Donoso M et al. · Medicine (2023)
In comparison to the use of a placebo, the findings suggest that ALA does not exhibit significant differences in terms of pain reduction and different functional scales.
Moreover, no specific dosages are identified to support the use of ALA for the reduction of neuropathic pain.
18Total cholesterol reductionMeta-AnalyseCited 33×n=452 · medium study2019
Effect sizes were combined with fixed- or random-effects analysis, where appropriate.
Mousavi SM et al. · Nutrition (Burbank, Los Angeles County, Calif.) (2019)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Effect sizes were combined with fixed- or random-effects analysis, where appropriate.
Eleven clinical trials with 452 adults (51.5% women, 48.5% men) were included in this meta-analysis.
We also found significant changes in serum total cholesterol and low-density lipoprotein (WMD, -10.683 mg/dL; 95% CI, -19.816 to -1.550; P = 0.022, WMD, -12.906 mg/dL; 95% CI, -22.133 to -3.679; P = 0.006, respectively).
19Total Symptom Score improvement in diabetic neuropathyMeta-AnalyseCited 6×n=11 · very small study2024
ALA and GLA appear to be safe and efficacious biofactors for improvement of DN symptoms.
Prado MB Jr et al. · Canadian journal of diabetes (2024)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Eight of the 11 articles (73%) reported significant benefit of ALA vs placebo.
In the meta-analysis, the Total Symptom Score (TSS) for ALA 600 mg/day (ALA600) was 1.05 points lower (standard mean difference [SMD] -1.05, 95% confidence interval [CI] -2.07 to -0.04, p=0.04, I2=98.18%) compared with control at the end of the study.
In the network meta-analysis, ALA600 (SMD -1.68, 95% CI -2.8 to -0.6) and GLA (SMD -2.39, 95% CI -4.3 to -0.5) had significantly lower TSSs compared with placebo.
A more significant volume in terms of sample size, multi-centres, and multi-arm comparison of therapeutic agents with placebo and longitudinal follow-up studies is recommended to establish a standardised burning mouth syndrome treatment protocol.
Tan HL et al. · Cephalalgia : an international journal of headache (2022)
A more significant volume in terms of sample size, multi-centres, and multi-arm comparison of therapeutic agents with placebo and longitudinal follow-up studies is recommended to establish a standardised burning mouth syndrome treatment protocol.